Jeremy Chrisp – CEO
Jeremy is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology, with a focus on business development and the management of early stage opportunities. Jeremy holds a PhD in physiology from the University of Canterbury (NZ) and is a Fellow of the Australian Institute of Company Directors (AICD). He has more than 30 years experience in the Australian healthcare market, initially by working with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.
Dr David Fuller – Acting CMO
David is a pharmaceutical physician with extensive experience in the clinical development, regulatory approval and commercialization of new therapeutic products. He specialises in the early stage development of oncology therapeutics and has more than 30 years international experience in the pharma/biotech sector for companies including Roche, Pfizer, Orphan Medical (US), Genzyme (Holland and UK), Arana Therapeutics and, more recently, Syneos Health (CRO). He has directly led four product approvals through the US FDA and EMA. David holds dual qualifications in Medicine and Pharmacy from the University of Sydney.
Darren Saunders – Chief Science Officer
Darren Saunders is a research scientist specialising in cancer biology, Associate Professor in Medicine at the University of Sydney and Senior Research Advisor to Elizabeth Broderick and Co. He undertook post-doctoral training at the Garvan Institute and University of British Columbia and has held fellowships from the US Dept. of Defense and Cancer Institute NSW. Darren has made significant contributions to leadership, governance and engagement through peak professional bodies and policy development.
Derek Bolling – CFO
Derek is a highly competent financial and accounting executive, gained from listed and unlisted companies and from high net wealth individuals. This includes engagements with higher education institutions, creative agencies, renewable energy technology providers and biotech start-ups. His experience in the Australian healthcare market includes working with companies such as Medsaic, Medical Therapies (now Cellmid), CathRx and Immune System Therapeutics.
Sudha Rao – Founding Scientist
Sudha is a Professor and Group Leader of the Gene Regulation and Translational Medicine Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. She is a domain expertise in epigenetics and cancer biology. Sudha completed her PhD at Kings College London prior to moving to industry, where she gained valuable drug development experience. This included the development of phase 1 and 2 assets in asthma, rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). Sudha was engaged by Aventis (now Sanofi) as a Senior Scientist for over 8 years before she was recruited to Australia to work under Professor Frances Shannon and later Professor Chris Parish at the Australian National University. More recently, she was recruited to the University of Canberra before joining QIMR Berghofer in late 2019.
Professor Alfredo Budillon, MD, PhD
Alfredo is an oncologist and an expert in experimental anticancer therapeutics and epigenetics. He is a Professor at the Comprehensive Cancer Center Istituto Nazionale dei Tumori G. Pascale of Napoli, Italy, where he is their Director of Experimental Pharmacology Unit. Professor Budillon is also the Director of the Proteomics and Metabolomics Programs at the Mercogliano Research Center, the high-technology facility branch of Institute Pascale.
Alfredo is author of more than 170 publications, most on the molecular mechanism of novel anticancer drugs, particularly epigenetic drugs, and the potential combination approaches with conventional drugs. Some of these findings were translated into clinical trials particularly in rectal and colon cancer patients. Recently he focused his research on targeting metabolic reprogramming in cancer cells, particularly in cancer stem cell compartment. Other scientific interests are related with System Biology approach and identification/validation of circulating prognostic/predictive biomarkers in liquid biopsies (i.e metabolites, EVs, Immune cell subpopulations).
Currently Alfredo is the Co-Chair of “Small Molecules” Platform at the European Infrastructure for Translational Medicine (EATRIS) and Member of the Board of A-IATRIS, the Italian Node of EATRIS.
Professor Roberto Pili, MD
Roberto’s research and practice interests include epigenetics, genitourinary cancer and nutritional treatment of cancer patients. He is Professor of Medicine, Chief of the Division of Hematology/Oncology and Associate Dean for Cancer Research in the Jacobs School of Medicine and Biomedical Sciences at University at Buffalo. He also holds a secondary appointment in the Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions. Additionally, Professor Pili is vice president for oncology services within Great Lakes Cancer Care Collaborative, a consortium of eight organisations including UBMD, Erie County Medical Center and Kaleida Health.
Roberto is a graduate of the Catholic University School of Medicine in Rome, Italy where he completed training in internal medicine, followed by an internal medicine residency at Montefiore Medical Center at the Albert Einstein College of Medicine in New York. Professor Pili did his postdoctoral fellowship in biological chemistry at the National Institutes of Health and a clinical-research fellowship in medical oncology at Johns Hopkins.
Jeanette Wood – Scientific Advisor
Jeanette is drug discovery expert with a PhD in Pharmacology from the University of Otago, Dunedin. Her early research focused on innovative small molecule drugs targeting the renin-angiotensin system and later, at Novartis, on therapies for cancer and inflammatory diseases. In both the cardiovascular and cancer areas, Jeanette successfully led various global drug discovery teams and research groups and she played a role in the discovery and/or profiling of several marketed drugs and compounds in the Novartis development portfolio.
Under her leadership at AstraZeneca, AZ9291 (Tagrisso), was selected for development and has recently been registered for the treatment of lung cancer patients with the EGFR resistance mutation, T790M. GKT771, a selective NOX1 inhibitor, was discovered and selected for development under her leadership in Genkyotex.
She has served as a Scientific and Strategic Advisor to numerous biotech companies and universities with drug discovery activities around the world.
Jeanette has also been an invited speaker at numerous scientific and career mentoring events and served as a part time lecturer at Departments of Pharmacy/Pharmacology in New Zealand, Switzerland, Korea and Singapore. She has been awarded several prizes for her scientific and drug discovery
excellence and is author of numerous patents and publications.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founding Scientist at EpiAxis Therapeutics